7Baggers
 Aprea Therapeutics Reports Ongoing Financial Challenges  TipRanks Thu, 13 Nov 2025 04:12:33 GMT
 Aprea Therapeutics Narrows Losses And Impresses Wall Street  Finimize Wed, 12 Nov 2025 15:14:02 GMT
 Aprea Therapeutics Reports Q3 Results and Clinical Updates  TipRanks Wed, 12 Nov 2025 14:03:15 GMT
 Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year  TipRanks Wed, 12 Nov 2025 13:58:14 GMT
 Aprea Therapeutics sees cash runway into 4Q26  TipRanks Wed, 12 Nov 2025 13:57:46 GMT
 Aprea Therapeutics' Q3 net loss narrows  TradingView Wed, 12 Nov 2025 13:38:02 GMT
 A President/CEO Of Aprea Therapeutics Inc (APRE) Buys 5500.0 Shares  fostersleader.com Wed, 05 Nov 2025 08:00:00 GMT
 Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge  openPR.com Mon, 03 Nov 2025 22:06:03 GMT
 international business times  FinancialContent Mon, 03 Nov 2025 21:31:00 GMT
 risk vs reward if holding onto aprea therapeutics inc.  newser.com Tue, 28 Oct 2025 09:20:33 GMT
 Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors  TipRanks Mon, 27 Oct 2025 07:00:00 GMT
 aprea therapeutics provides update from acesot-1051 t rial  TipRanks Fri, 24 Oct 2025 14:16:48 GMT
 aprea therapeutics provides clinical update on acesot-1051 trial  TradingView Fri, 24 Oct 2025 12:45:00 GMT
 Aprea Therapeutics Reports Promising Trial Results for APR-1051  TipRanks Fri, 24 Oct 2025 07:00:00 GMT
 Aprea’s WEE1 inhibitor shows disease stabilization in early trial  Investing.com Fri, 24 Oct 2025 07:00:00 GMT
 aprea sees early activity in apr-1051 wee1 trial  MarketScreener Fri, 24 Oct 2025 07:00:00 GMT
 aprea therapeutics establishes rp2d for atrn-119  MSN Thu, 16 Oct 2025 07:24:42 GMT
 Aprea Therapeutics Shifts Focus to Combination Therapies  TipRanks Wed, 15 Oct 2025 07:00:00 GMT
 aprea therapeutics establishes rp2d for atrn-119  TipRanks Wed, 15 Oct 2025 07:00:00 GMT
 Aprea Therapeutics Announces Presentations at  GlobeNewswire Tue, 14 Oct 2025 07:00:00 GMT

Aprea Therapeutics, Inc
(NASDAQ:APRE) 

APRE stock logo

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical d...

Founded: 2006
IPO Price: $15 (Oct 03, 2019)
Full Time Employees: 13
CEO: Christian S. Schade  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends